Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Plasmapheresis therapy in systemic sclerosis].

Gabriella Szúcs1, Szilvia Szamosi, Magdolna Aleksza

  • 1Debreceni Egyetem, Orvos- és Egészségtudományi Centrum, Altalános Orvostudományi Kar, III. Belgyógyászati Klinika, Reumatológia Tanszek, Immunológiai Tanszek.

Orvosi Hetilap
|December 23, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inflammatory Bowel Disease-Associated Spondyloarthritis.

Journal of clinical medicine·2026
Same author

Current Knowledge of the Genus <i>Satureja</i>: A Comprehensive Review of Its Traditional Use, Phytochemistry, Pharmacological Activity and Non-Medical Applications.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Checkpoint Inhibitor-Induced Raynaud's Phenomenon, Hypothyroidism, and Pneumonitis in Head and Neck Cancer: A Case Report.

Cureus·2026
Same author

Diagnostic, prognostic and therapeutic biomarkers in rheumatoid arthritis.

Nature reviews. Rheumatology·2026
Same author

Clinical Relevance and Methodological Comparison of Anti-MDA5 Antibody Detection: A Five-Year Retrospective and Exploratory Pilot Study.

Biomolecules·2026
Same author

Real-World Data on Halting Radiographic Progression with Antifibrotics in Connective Tissue Disease-Associated Interstitial Lung Disease: A Two-Center Study from Hungary.

Journal of clinical medicine·2026

Plasmapheresis may slow systemic sclerosis (SSc) progression and improve skin symptoms in early diffuse cutaneous SSc. This treatment reduced disease activity markers and slowed progression in four patients.

Area of Science:

  • Rheumatology
  • Immunology
  • Nephrology

Background:

  • Systemic sclerosis (SSc) is an autoimmune disease causing excessive extracellular matrix production and vascular issues.
  • Current SSc treatments lack disease-modifying capabilities, with limited research on plasmapheresis efficacy.
  • Diffuse cutaneous SSc presents with rapid progression and multi-organ involvement.

Observation:

  • Four patients with early diffuse cutaneous SSc underwent plasmapheresis every three months.
  • Treatment was combined with standard symptomatic drug therapy.
  • Evaluations included clinical symptoms, Rodnan skin score, immunolaboratory markers, and soluble adhesion molecules.

Findings:

  • Plasmapheresis significantly slowed disease progression and prevented new manifestations.

Related Experiment Videos

  • Rodnan skin score decreased, indicating improvement in skin involvement.
  • Key markers like CD4/CD8 ratio, CD69 expression, and soluble adhesion molecules showed significant reduction.

    • Implications:

    • Plasmapheresis shows potential as an effective early-phase treatment for diffuse cutaneous SSc.
    • The therapy may improve clinical symptoms, particularly skin manifestations.
    • Further research is warranted to confirm plasmapheresis efficacy in SSc management.